Prostate Cancer | Meet The Professor: Optimizing the Management of Metastatic Castration-Resistant Prostate Cancer — Part 3

Featuring perspectives from Prof Karim Fizazi, including the following topics: Introduction (0:00) Journal Club with Prof Karim Fizazi, MD, PhD (3:40) Case: A man in his late 60s with metastatic hormone-sensitive prostate cancer — Nataliya Mar, MD (16:39) Comments on the PEACE-1 trial by A Oliver Sartor, MD (21:58) Case: Two patients with prostate cancer who received a PARP inhibitor — Helen H Moon, MD (32:18) Case: A man in his mid-60s with metastatic castration-resistant prostate cancer (mCRPC) and a somatic BRCA2 mutation — Rohit Gosain, MD (37:59) Second Opinion by Simon Chowdhury, MD, PhD: A man in his late 60s with mCRPC and a germline BRCA2 mutation (Zanetta S Lamar, MD) (41:40) Comments on the TheraP trial by Dr Sartor (55:29) Immune Checkpoint Inhibitors in mCRPC (58:48) CME information and select publications